{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '11. ECG [within 7 days prior to starting study treatment and as clinically indicated]', '12. Blood for exploratory biomarkers [Cycle 1, Day 1 and Cycle 1, Day 8 (+/-7 days;', 'optional)]', '13. Optional metastatic biopsy [Cycle 1, Day 8 (+/- 7 days)]', '14. Quality of life questionnaires (FACT-P and IIEF) [Every 3 cycles]', '15. Brief pain inventory [Every cycle]', '5.2.3', 'End of study', 'End of Study is defined as the last visit where the decision is made to discontinue treatment.', 'All required procedures must be completed within 30 days of receiving the last dose of study', 'drug(s). Treatment/Intervention Period assessments may used for the End of Study timepoint', 'if within the 30 day timeframe.', '1. Comprehensive medical history and physical exam, including weight, medication', 'reconciliation, blood pressure, heart rate and ECOG performance status assessment', '2. Unused olaparib collection', '3. CBC (Complete blood count) with differential and platelet count', '4. CMP (Comprehensive Metabolic Panel - Sodium, Potassium, Chloride, BUN,', 'Serum Creatinine, Calcium, Total Protein, Albumin, Total Bilirubin, AST, ALT,', 'Alkaline Phosphatase, CO2)', '5. PSA', '6. Radiologic tests (i.e., CT chest/abdomen/pelvis and bone scan)', '7. Blood for exploratory biomarkers', '8. Optional metastatic biopsy', '9. Quality of life questionnaires (FACT-P and IIEF)', '10. Brief pain inventory', '42(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '5.2.4', 'Follow Up', 'A 30-day safety follow-up will be required (+/-7 days). End of Study assessments may be', 'used for the follow-up timepoint if these have occurred +/-7 days of the follow-up visit.', '1. Comprehensive medical history and physical exam, including weight, medication', 'reconciliation, blood pressure, heart rate and ECOG performance status assessment', '2. CBC (Complete blood count) with differential and platelet count', '3. CMP (Comprehensive Metabolic Panel - Sodium, Potassium, Chloride, BUN,', 'Serum Creatinine, Calcium, Total Protein, Albumin, Total Bilirubin, AST, ALT,', 'Alkaline Phosphatase, CO2)', '5.2.5', 'Long-term Follow Up', 'The Long-term Follow Up assessment is to confirm if patient is still alive, and to document', 'the date of death if deceased. This may be conducted in person or remotely (i.e., via phone,', 'email or postal). Long-term Follow Up will occur every 6 months (+/- 30 days) up to 2 years', 'following last dose of study drug(s) or sooner if the study is terminated.', '43(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Study calendar', 'Treatment/Intervention Period', 'Screening', 'End of Study', 'Follow Upb', 'Long-term', 'Cycle 1a', 'Cycle 2', 'Cycle 3', 'Cycle 4', 'Cycle >5', 'Follow up\u00b0', '<30 d from', 'Every 6', 'Day -30', 'Day 1 (+7', 'Day 8 (+7', 'Day 1 (+7', 'Day 1 (+7', 'Day 1 (+7', 'Day 1 (+7', '30 d (+3 d) from last', 'stopping', 'months (+30', 'to 0', 'd)', 'd)', 'd)', 'd)', 'd)', 'd)', 'dose of study drug(s)', 'treatment', 'd)', 'Informed', 'X', 'consent', 'Treatment with', 'testosterone', 'X', 'X', 'X', 'X', 'Every Cycle', 'enanthate/cypio', 'nate', 'Olaparib', 'X', 'X', 'X', 'X', 'Every Cycle', 'dispensation', 'Unused olaparib', 'X', 'X', 'X', 'Every Cycle', 'X', 'collection', 'Demographics', 'X', 'Medical history', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'X', 'Physical', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'X', 'assessment', 'Vital signs', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'X', 'Height', 'X', 'Weight', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'X', 'Performance', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'X', 'status', 'ECGd', 'X', 'Every 3', 'Radiologic testse', 'X', 'X', 'X', 'Cyclesh', 'CBC with diff', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'X', 'CMP', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'X', 'PSA', 'X', 'X', 'X', 'X', 'X', 'Every Cycle', 'X', 'Serum', 'X', 'X', 'X', 'Testosterone', '44(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}